BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1253 related articles for article (PubMed ID: 2937629)

  • 1. Use of a potent, long acting agonist of gonadotropin-releasing hormone in the treatment of precocious puberty.
    Boepple PA; Mansfield MJ; Wierman ME; Rudlin CR; Bode HH; Crigler JF; Crawford JD; Crowley WF
    Endocr Rev; 1986 Feb; 7(1):24-33. PubMed ID: 2937629
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Changes in growth and serum growth hormone and plasma somatomedin-C levels during suppression of gonadal sex steroid secretion in girls with central precocious puberty.
    Mansfield MJ; Rudlin CR; Crigler JF; Karol KA; Crawford JD; Boepple PA; Crowley WF
    J Clin Endocrinol Metab; 1988 Jan; 66(1):3-9. PubMed ID: 2961786
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment of true precocious puberty with a potent luteinizing hormone-releasing factor agonist: effect on growth, sexual maturation, pelvic sonography, and the hypothalamic-pituitary-gonadal axis.
    Styne DM; Harris DA; Egli CA; Conte FA; Kaplan SL; Rivier J; Vale W; Grumbach MM
    J Clin Endocrinol Metab; 1985 Jul; 61(1):142-51. PubMed ID: 3923027
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The NIH experience with precocious puberty: diagnostic subgroups and response to short-term luteinizing hormone releasing hormone analogue therapy.
    Pescovitz OH; Comite F; Hench K; Barnes K; McNemar A; Foster C; Kenigsberg D; Loriaux DL; Cutler GB
    J Pediatr; 1986 Jan; 108(1):47-54. PubMed ID: 3080571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Somatomedin-C in normal puberty and in true precocious puberty before and after treatment with a potent luteinizing hormone-releasing hormone agonist.
    Harris DA; Van Vliet G; Egli CA; Grumbach MM; Kaplan SL; Styne DM; Vainsel M
    J Clin Endocrinol Metab; 1985 Jul; 61(1):152-9. PubMed ID: 3889035
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Serum insulin-like growth factor I (IGF-I) and IGF-binding protein 3 levels are increased in central precocious puberty: effects of two different treatment regimens with gonadotropin-releasing hormone agonists, without or in combination with an antiandrogen (cyproterone acetate).
    Juul A; Scheike T; Nielsen CT; Krabbe S; Müller J; Skakkebaek NE
    J Clin Endocrinol Metab; 1995 Oct; 80(10):3059-67. PubMed ID: 7559897
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Adrenarche and skeletal maturation during luteinizing hormone releasing hormone analogue suppression of gonadarche.
    Wierman ME; Beardsworth DE; Crawford JD; Crigler JF; Mansfield MJ; Bode HH; Boepple PA; Kushner DC; Crowley WF
    J Clin Invest; 1986 Jan; 77(1):121-6. PubMed ID: 2935557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Luteinizing hormone-releasing hormone analog treatment of boys with hypothalamic hamartoma and true precocious puberty.
    Comite F; Pescovitz OH; Rieth KG; Dwyer AJ; Hench K; McNemar A; Loriaux DL; Cutler GB
    J Clin Endocrinol Metab; 1984 Nov; 59(5):888-92. PubMed ID: 6434587
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adult height in girls with central precocious puberty treated with gonadotropin-releasing hormone analogues and growth hormone.
    Pasquino AM; Pucarelli I; Segni M; Matrunola M; Cerroni F
    J Clin Endocrinol Metab; 1999 Feb; 84(2):449-52. PubMed ID: 10022399
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Long-term treatment of central precocious puberty with a long-acting analogue of luteinizing hormone-releasing hormone. Effects on somatic growth and skeletal maturation.
    Mansfield MJ; Beardsworth DE; Loughlin JS; Crawford JD; Bode HH; Rivier J; Vale W; Kushner DC; Crigler JF; Crowley WF
    N Engl J Med; 1983 Nov; 309(21):1286-90. PubMed ID: 6415479
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reproductive axis after discontinuation of gonadotropin-releasing hormone analog treatment of girls with precocious puberty: long term follow-up comparing girls with hypothalamic hamartoma to those with idiopathic precocious puberty.
    Feuillan PP; Jones JV; Barnes K; Oerter-Klein K; Cutler GB
    J Clin Endocrinol Metab; 1999 Jan; 84(1):44-9. PubMed ID: 9920060
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Gonadotropin-independent familial sexual precocity with premature Leydig and germinal cell maturation (familial testotoxicosis): effects of a potent luteinizing hormone-releasing factor agonist and medroxyprogesterone acetate therapy in four cases.
    Rosenthal SM; Grumbach MM; Kaplan SL
    J Clin Endocrinol Metab; 1983 Sep; 57(3):571-9. PubMed ID: 6223935
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The relationship between luteinizing hormone and estradiol secretion in female precocious puberty: evaluation by sensitive gonadotropin assays and the leuprolide stimulation test.
    Garibaldi LR; Aceto T; Weber C; Pang S
    J Clin Endocrinol Metab; 1993 Apr; 76(4):851-6. PubMed ID: 8473395
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of deslorelin dose in the treatment of central precocious puberty.
    Pescovitz OH; Barnes KM; Cutler GB
    J Clin Endocrinol Metab; 1991 Jan; 72(1):60-4. PubMed ID: 1898743
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Long term treatment of male and female precocious puberty by periodic administration of a long-acting preparation of D-Trp6-luteinizing hormone-releasing hormone microcapsules.
    Roger M; Chaussain JL; Berlier P; Bost M; Canlorbe P; Colle M; Francois R; Garandeau P; Lahlou N; Morel Y
    J Clin Endocrinol Metab; 1986 Apr; 62(4):670-7. PubMed ID: 2936759
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Resumption of puberty after long term luteinizing hormone-releasing hormone agonist treatment of central precocious puberty.
    Manasco PK; Pescovitz OH; Feuillan PP; Hench KD; Barnes KM; Jones J; Hill SC; Loriaux DL; Cutler GB
    J Clin Endocrinol Metab; 1988 Aug; 67(2):368-72. PubMed ID: 3292562
    [TBL] [Abstract][Full Text] [Related]  

  • 17. True precocious puberty complicating congenital adrenal hyperplasia: treatment with a luteinizing hormone-releasing hormone analog.
    Pescovitz OH; Comite F; Cassorla F; Dwyer AJ; Poth MA; Sperling MA; Hench K; McNemar A; Skerda M; Loriaux DL
    J Clin Endocrinol Metab; 1984 May; 58(5):857-61. PubMed ID: 6368580
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined therapy with GnRH analog plus growth hormone in central precocious puberty.
    Pucarelli I; Segni M; Ortore M; Moretti A; Iannaccone R; Pasquino AM
    J Pediatr Endocrinol Metab; 2000 Jul; 13 Suppl 1():811-20. PubMed ID: 10969926
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suppression of the pituitary-gonadal axis in children with central precocious puberty: effects on growth, growth hormone, insulin-like growth factor-I, and prolactin secretion.
    Sklar CA; Rothenberg S; Blumberg D; Oberfield SE; Levine LS; David R
    J Clin Endocrinol Metab; 1991 Oct; 73(4):734-8. PubMed ID: 1909701
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Luteinizing hormone releasing hormone analogue therapy for central precocious puberty. Long-term effect on somatic growth, bone maturation, and predicted height.
    Comite F; Cassorla F; Barnes KM; Hench KD; Dwyer A; Skerda MC; Loriaux DL; Cutler GB; Pescovitz OH
    JAMA; 1986 May; 255(19):2613-6. PubMed ID: 3084811
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 63.